99 related articles for article (PubMed ID: 22797653)
1. Darunavir: a critical review of its properties, use and drug interactions.
Ruela Corrêa JC; D'Arcy DM; dos Reis Serra CH; Nunes Salgado HR
Pharmacology; 2012; 90(1-2):102-9. PubMed ID: 22797653
[TBL] [Abstract][Full Text] [Related]
2. Darunavir: a nonpeptidic antiretroviral protease inhibitor.
McCoy C
Clin Ther; 2007 Aug; 29(8):1559-76. PubMed ID: 17919539
[TBL] [Abstract][Full Text] [Related]
3. Darunavir: pharmacokinetics and drug interactions.
Back D; Sekar V; Hoetelmans RM
Antivir Ther; 2008; 13(1):1-13. PubMed ID: 18389894
[TBL] [Abstract][Full Text] [Related]
4. Darunavir: an overview of an HIV protease inhibitor developed to overcome drug resistance.
Taiwo BO; Hicks CB
AIDS Read; 2007 Mar; 17(3):151-6, 159-61. PubMed ID: 17396332
[TBL] [Abstract][Full Text] [Related]
5. Darunavir (TMC114): a new HIV-1 protease inhibitor.
Molina JM; Hill A
Expert Opin Pharmacother; 2007 Aug; 8(12):1951-64. PubMed ID: 17696796
[TBL] [Abstract][Full Text] [Related]
6. Darunavir: an effective protease inhibitor for HIV-infected patients.
Phung BC; Yeni P
Expert Rev Anti Infect Ther; 2011 Jun; 9(6):631-43. PubMed ID: 21692667
[TBL] [Abstract][Full Text] [Related]
7. Darunavir.
El-Atrouni WI; Temesgen Z
Drugs Today (Barc); 2007 Oct; 43(10):671-9. PubMed ID: 17987220
[TBL] [Abstract][Full Text] [Related]
8. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
[TBL] [Abstract][Full Text] [Related]
9. New therapeutic agents in the management of HIV: an overview of darunavir for clinicians.
Rotty J; Hoy J
Sex Health; 2008 Sep; 5(3):235-41. PubMed ID: 18771638
[TBL] [Abstract][Full Text] [Related]
10. Treatment simplification to once daily darunavir/ritonavir guided by the darunavir inhibitory quotient in heavily pretreated HIV-infected patients.
Moltó J; Valle M; Santos JR; Mothe B; Miranda C; Cedeño S; Negredo E; Yritia M; Videla S; Barbanoj MJ; Clotet B
Antivir Ther; 2010; 15(2):219-25. PubMed ID: 20386077
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.
Poveda E; de Mendoza C; Martin-Carbonero L; Corral A; Briz V; González-Lahoz J; Soriano V
J Antimicrob Chemother; 2007 Oct; 60(4):885-8. PubMed ID: 17646201
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.
Young J; Scherrer AU; Günthard HF; Opravil M; Yerly S; Böni J; Rickenbach M; Fux CA; Cavassini M; Bernasconi E; Vernazza P; Hirschel B; Battegay M; Bucher HC;
HIV Med; 2011 May; 12(5):299-307. PubMed ID: 20955357
[TBL] [Abstract][Full Text] [Related]
13. Darunavir: a second-generation protease inhibitor.
Busse KH; Penzak SR
Am J Health Syst Pharm; 2007 Aug; 64(15):1593-602. PubMed ID: 17646561
[TBL] [Abstract][Full Text] [Related]
14. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
Pellegrin I; Wittkop L; Joubert LM; Neau D; Bollens D; Bonarek M; Girard PM; Fleury H; Winters B; Saux MC; Pellegrin JL; Thiébaut R; Breilh D;
Antivir Ther; 2008; 13(2):271-9. PubMed ID: 18505178
[TBL] [Abstract][Full Text] [Related]
15. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
Prescrire Int; 2008 Aug; 17(96):135-7. PubMed ID: 19480091
[TBL] [Abstract][Full Text] [Related]
16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
17. Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
Di Biagio A; Rosso R; Bruzzone B; Cenderello G; Dentone C; Mularoni A; Ferrea G; Icardi G; Viscoli C
AIDS; 2008 Jan; 22(3):437-8. PubMed ID: 18195574
[No Abstract] [Full Text] [Related]
18. [Preserving future therapy options. Darunavir--the protease inhibitor for various patient groups].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():24-5. PubMed ID: 19024912
[No Abstract] [Full Text] [Related]
19. Response to "key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients".
Picchio G; De Meyer S; de Béthune MP
AIDS; 2008 Jan; 22(1):165-7. PubMed ID: 18090413
[No Abstract] [Full Text] [Related]
20. Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases.
Rawizza HE; Sax PE
AIDS Read; 2008 Sep; 18(9):466-72, 478-9. PubMed ID: 18828231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
